Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses

详细信息    查看全文

• 作者：Mustafa Kilickap ; MD ; MSc^a ; ^{mkilickap@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Jackie Bosch ; PhD^b ; John W. Eikelboom ; MBBS ; MSc^b ; Robert G. Hart ; MD^b
• 刊名：Canadian Journal of Cardiology
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：32
• 期：9
• 页码：1108-1116
• 全文大小：883 K

文摘

Atrial fibrillation (AF) is a common cardiac rhythm disturbance and is associated with a 5-fold increased risk of stroke. The most important risk factors for stroke in patients with AF are previous stroke and age ≥ 75 years. Canadian guidelines recommend anticoagulant therapy for patients with AF who are older than the age of 65 years, but the elderly often remain undertreated, primarily because of concerns regarding bleeding. Non-vitamin K oral anticoagulants appear to be safer, at least as efficacious, and more convenient than warfarin, and are a cost-effective alternative for elderly patients with AF. We review the evidence for the use of antithrombotic agents for stroke prevention in elderly patients (age ≥ 75 years) with nonvalvular AF.